# EDGAR Filing Document

**Accession Number:** 0001932843
**File Stem:** 0001829126-26-004051
**Filing Date:** 2026-4
**Character Count:** 13406
**Document Hash:** 126022573382fc50c0b6b3acea0214f0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001829126-26-004051.hdr.sgml**: 20260428

**ACCESSION NUMBER**: 0001829126-26-004051

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260428

**DATE AS OF CHANGE**: 20260428

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Quantum Cyber N.V.
- **CENTRAL INDEX KEY:** 0001874252
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93665
- **FILM NUMBER:** 26909483

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** ROBERT KOCH STRASSE 50
- **CITY:** MAINZ
- **PROVINCE COUNTRY:** 2M
- **BUSINESS PHONE:** 49 6131 5542860

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** ROBERT KOCH STRASSE 50
- **CITY:** MAINZ
- **PROVINCE COUNTRY:** 2M

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MAINZ BIOMED N.V.
- **DATE OF NAME CHANGE:** 20211112

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Mainz Biomed B.V.
- **DATE OF NAME CHANGE:** 20210721
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lazar David E.
- **CENTRAL INDEX KEY:** 0001932843

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 44, TOWER 100, THE TOWERS
- **STREET 2:** WINSTON CHURCHILL, PAITILLA
- **CITY:** PANAMA CITY
- **PROVINCE COUNTRY:** R1

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**MAINZ BIOMED N.V.**

*(Name of Issuer)*

**Ordinary Shares, (euro)0.01 nominal value**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**DAVID E. LAZAR**<br>44, Tower 100, The Towers Winston<br>Churchill San Francisco, Paitilla<br>Panama City R1 07196<br>646-768-8417

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**04/22/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Lazar David E.** | Name of reporting person<br>**Lazar David E.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**S1** | Citizenship or place of organization<br>**S1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**477000000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**477000000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**477000000.00** | Aggregate amount beneficially owned by each reporting person<br>**477000000.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**97.4%** | Percent of class represented by amount in Row (11)<br>**97.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Consists of (i) 9,000,000 Ordinary Shares issuable upon conversion of the Issuer's Series A Preferred Shares, (ii) 9,000,000 Ordinary Shares issuable upon conversion of the Issuer's Series B Preferred Shares, (iii) 9,000,000 Ordinary Shares issuable upon conversion of the Issuer's Series C Preferred Shares, (iv) 225,000,000 Ordinary Shares issuable upon conversion of the Issuer's Series D Preferred Shares, and (v) 225,000,000 Ordinary Shares issuable upon conversion of the Issuer's Series E Preferred Shares.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares, (euro)0.01 nominal value

**(b) Name of Issuer:**
MAINZ BIOMED N.V.

**(c) Address of Issuer's Principal Executive Offices:**
ROBERT KOCH STRASSE 50, 55129, MAINZ, 2M, 55129

**Item 4. Purpose of Transaction**

Pursuant to the SPA, as further described in Item 6, effective as of February 13, 2026, the Reporting Person was appointed as a temporary non-executive director and Chair of the Board of Directors of the Issuer. At the Issuer's shareholder meeting held on April 22, 2026 (the "Meeting"), the Issuer's shareholders approved, among other matters, (a) the conversion of the Preferred Shares into Ordinary Shares, (b) the appointment of the Reporting Person as an executive director and Chief Executive Officer, and (c) the appointment of the Reporting Person's designees to the Board of Directors.

The Reporting Person purchased the Shares pursuant to the SPA based on the Reporting Person's belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Person, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Person may endeavor to increase or decrease his position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Person may deem advisable.

The Reporting Person does not have any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Person intends to review his investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Person may in the future take such actions with respect to his investment in the Issuer as he deems appropriate including, without limitation, engaging in additional communications with management and the Board of Directors of the Issuer, engaging in discussions with shareholders of the Issuer or other third parties about the Issuer and the Reporting Person's investment, including potential business combinations or dispositions involving the Issuer or certain of its businesses, making recommendations or proposals to the Issuer concerning changes to the capitalization, ownership structure, board structure (including board composition), potential business combinations or dispositions involving the Issuer or certain of its businesses, or suggestions for improving the Issuer's financial and/or operational performance, purchasing additional Shares, selling some or all of his Shares, engaging in short selling of or any hedging or similar transaction with respect to the Shares, including swaps and other derivative instruments, or changing his intention with respect to any and all matters referred to in Item 4.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The aggregate percentage of Ordinary Shares owned by the Reporting Person is based upon (a) 12,515,336 Ordinary Shares outstanding as of March 25, 2026, as reported in the Issuer's Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on March 31, 2026, and (b) 477,000,000 Shares issuable to the Reporting Person upon the conversion of the Preferred Shares.

As of the close of business on April 22, 2026, following the receipt of Stockholder Approval at the Meeting, the Reporting Person beneficially owned 477,000,000 Shares issuable upon conversion of the Preferred Shares.

Percentage: Approximately 97.4%

**(b)**
1. Sole power to vote or direct vote: 477,000,000
2. Shared power to vote or direct vote: 0
3. Sole power to dispose or direct the disposition: 477,000,000
4. Shared power to dispose or direct the disposition: 0

**(c)**
The transactions in the Shares by the Reporting Person during the past sixty days are set forth in more detail in Item 6.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

On February 13, 2026, the Issuer entered into the SPA with the Reporting Person, pursuant to which the Reporting Person agreed to acquire from the Issuer (i) simultaneous to entering into the SPA (the "First Closing"), 1,000,000 Series A Preferred Shares, 1,000,000 Series B Preferred Shares, and 1,000,000 Series C Preferred Shares (collectively, the "First Closing Shares") for an aggregate purchase price of $3,000,000, and (ii) shortly following the receipt of Stockholder Approval (as defined in the SPA) (the "Second Closing"), 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares (collectively, the "Second Closing Shares" and together with the First Closing Shares, the "Preferred Shares") for an aggregate purchase price of $3,000,000. The First Closing occurred on February 13, 2026, and the Second Closing occurred promptly after the Meeting on April 22, 2026 at which the Issuer obtained Stockholder Approval.

Each Series A, Series B, and Series C Preferred Share is convertible into 9 Ordinary Shares, and each Series D and Series E Preferred Share is convertible into 225 Ordinary Shares. Following the receipt of Stockholder Approval at the Meeting, all Preferred Shares are now fully convertible at the option of the holder for no further consideration.

Under the applicable Nasdaq Stock Market ("Nasdaq") rules and the SPA, prior to Stockholder Approval, the First Closing Shares were not convertible into Ordinary Shares at the time of the SPA. At the Meeting on April 22, 2026, the Issuer's shareholders approved (a) an increase in the Issuer's authorized ordinary shares to 900,000,000, (b) the conversion of all Preferred Shares into Ordinary Shares in compliance with the rules and regulations of Nasdaq, (c) a reverse stock split, (d) the appointment of the Reporting Person as an executive director and Chief Executive Officer, and (e) certain other matters required under the SPA.

The SPA contains customary representations, warranties and agreements of the Issuer and the Reporting Person, limitations, and conditions regarding sales of the Ordinary Shares, indemnification rights and other obligations of the parties. The SPA also contains certain covenants that the Issuer was obligated to comply with, including holding a shareholders' meeting for purposes of obtaining Stockholder Approval, which was obtained at the April 22, 2026 Meeting.

Pursuant to the SPA, immediately prior to the execution of the SPA, the Reporting Person was appointed as a temporary non-executive director and Chair of the Board of Directors of the Issuer. However, at the April 22, 2026 Meeting, the Issuer's shareholders approved the appointment of the Reporting Person as an executive director and Chief Executive Officer. In addition, certain of the Reporting Person's designees were voted onto the Board of Directors by the Issuer's shareholders.

At the Meeting, the Issuer obtained Stockholder Approval for all proposals set forth in the Issuer's Definitive Proxy Statement, including the conversion of all Preferred Shares into Ordinary Shares. As a result, all ownership limitations on conversion of the Preferred Shares were removed. Following the Meeting, the Second Closing occurred, at which time the Reporting Person acquired 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares for an aggregate purchase price of $3,000,000.

Following the Meeting and the Second Closing, all 5,000,000 Preferred Shares held by the Reporting Person are now fully convertible into an aggregate of 477,000,000 Ordinary Shares at the option of the Reporting Person.

The foregoing description of the SPA does not purport to be complete and is qualified in its entirety by reference to the SPA, which is filed as an exhibit to this Schedule 13D, and is incorporated by reference herein.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Lazar David E.

**Signature:** /s/ David E. Lazar

**Name/Title:** David E. Lazar

**Date:** 04/28/2026